Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graft Versus Host Disease Graft vs Host Disease Immune System Diseases

Age range

3 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Michigan Cancer Center

Ann Arbor, Michigan, 48109, United States

About this study

Completion date provided represents the completion date of the grant per OOPD records

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor

Treatment and study plan

recombinant human keratinocyte growth factor

Drug

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Registry information

Official study title

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Important dates

Study start: 2002
Study completion: 2005
First posted: Mar 27, 2003
Registry last updated: Mar 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed